FLT3 and acute myeloid leukemia: Inhibition with FLT3 TKIs can reverse Venetoclax resistance in FLT3 mutant cells.33 FLT3 TKIs could effectively downregulate MCL-1 expression, thus re-sensitizing AML cells to Venetoclax treatment.32,34,35 In the present study, we demonstrated that Gilteritinib, a recent FDA approved highly effective FLT3 TKI, or the combination of Gilteritinib and Venetoclax significantly downregulates MCL-1 expression.